Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / TIRZEPATIDE
FDA-approvedHigh for approved indication
Tirzepatide
ALSO KNOWN ASZepbound · Mounjaro
A dual GIP/GLP-1 peptide agonist with strong evidence for obesity and type 2 diabetes.
01CATEGORYMetabolic & fat loss
02REGULATORY STATUSFDA-approved
03COMMON ROUTESubcutaneous injection once weekly
04DOSE BASISFDA-approved label
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Tirzepatide is.
A synthetic peptide that activates both glucose-dependent insulinotropic polypeptide and GLP-1 receptors. Zepbound and Mounjaro carry different labeled indications.
HOW IT IS THOUGHT TO WORK
Changes appetite and energy intake while improving glucose-dependent insulin signaling, glucagon regulation and gastric emptying.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Large average weight reduction in eligible adults in randomized trials
- Improved glycemic control in type 2 diabetes
- Improvement in moderate-to-severe obstructive sleep apnea in the labeled obesity population
- That higher dose is always better
- That compounded versions are clinically interchangeable with approved products
- A safe cosmetic shortcut without long-term nutrition and medical oversight
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
FDA-APPROVED LABELLabeling begins at 2.5 mg once weekly for 4 weeks, then 5 mg weekly. Maintenance is individualized; labeled options include 5, 10 or 15 mg weekly with increases no faster than 2.5 mg every 4 weeks.
- Route
- Subcutaneous injection once weekly
- Duration
- Long-term treatment when benefits outweigh risks
- Men & women
- No routine dose difference by sex. Oral contraceptive absorption may be affected during initiation and dose escalation; pregnancy requires prescriber guidance.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Weight and waist trend
- Glucose and diabetes medications
- GI tolerance, hydration and gallbladder symptoms
- Nutrition quality, protein intake and lean mass
SAFETY
Risks, red flags and reasons to avoid it.
- Nausea, diarrhea, vomiting, constipation and abdominal symptoms
- Gallbladder disease, pancreatitis warning and dehydration-related kidney injury
- Hypoglycemia with insulin or secretagogues
- Boxed thyroid C-cell tumor warning
- Pregnancy
- Personal/family MTC or MEN2
- Concurrent tirzepatide or GLP-1 products
- Unverified compounded or research products
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved products. Retatrutide is a different molecule and is not an approved substitute.
The approved drug has robust evidence. Online products that borrow its language may not have FDA-reviewed identity, sterility, potency or dosing devices.
Compare qualified specialists
Coming soon: indication-matched clinicians, transparent pricing, required monitoring and verified prescription sourcing.
Join the treatment shortlist →NEXT STEP